References
=20
Agid, Y., et al. 1993. Are dopaminergic neurons
selectively vulnerable to Parkinson's disease? Pages
148-164 in H. Narabayashi, T. Nagatsu, N. Yanagisawa,
and Y. Mizuno, eds. Advances in neurology (vol. 60):
Parkinson's disease-from basic research to treatment.=20
New York, NY
Albin, R.L., A.B. Young, and J.B. Penney. 1989 The
functional anatomy of basal ganglia disorders. Trends
Neurosci. 12:366-375.
Alexander, G.E., and M.D. Crutcher. 1990 Functional
architecture of basal ganglia circuits: neural substrates
of parallel processing. Trends Neurosci. 13:266-271.
Barbeau, A., R.M. Cloutier, et al. 1986. Environmental
and genetic factors in Parkinson's disease. Pages 299-
306 in M.D. Yahr and K.J. Bergman, eds. Advances in
neurology (vol. 45): Parkinson's disease. New York, NY
Beal, M.F., B.T. Hyman, and W. Koroshetz. 1993 Do
defects in mitochondrial energy metabolism underlie the
pathology of neurodegenerative diseases?. Trends
Neurosci. 16:125-132
Bj=94rklund, A. and U. Stenevi. 1979 Regeneration of
monoaminergic and cholinergic neurons in the mammalian
central nervous system. Physiol. Rev. 59:62-100
Brown, R.G. and C.D. Marsden. 1988 Internal versus
external cues and the control of attention in Parkinson's
disease. Brain 111:323-345
Calne, D.B. 1993 Treatment of Parkinson's disease. New
Eng. J. Med 329(14):1021-1027.
Cash, R., T. Dennis, et al. 1987 Parkinson's disease
and dementia: norepinephrine and dopamine in locus
ceruleus. Neurology 37:42-46
Chiueh, C.C., H Miyake, and M. Peng. 1993. Role of
dopamine autoxidation, hydroxyl radical generation, and
calcium overload in underlying mechanisms involved in
MPTP-induced parkinsonism. Pages 251-258 in H.
Narabayashi, T. Nagatsu, N. Yanagisawa, and Y. Mizuno,
eds. Advances in neurology (vol. 60): Parkinson's
disease-from basic research to treatment. New York, NY
D'Amato, R.J., G.M. Alexander, R.J. Schwartzman, et al.=20
1987 Evidence for neuromelanin involvement in
MPTP-induced neurotoxicity. Nature 327: 324-327
DeLong, M.R. 1990 Primate models of movement disorders
of basal ganglia origin. Trends Neurosci. 13:281-285.
Fahn, S. 1989. Adverse effects of levodopa in
Parkinson's disease. Pages 385-409 in D.B. Calne, ed.=20
Drugs for the treatment of Parkinson's disease. Berlin,
Germany
Freund, H. and H. Hefter. 1993. The role of basal
ganglia in rhythmic movement. Pages 88-92 in H.
Narabayashi, T. Nagatsu, N. Yanagisawa, and Y. Mizuno,
eds. Advances in neurology (vol. 60): Parkinson's
disease-from basic research to treatment. New York, NY
Golbe, L.I., T.M. Farrell, P.H. Davis. 1990 Follow-up
study of early-life protective and risk factors in
Parkinson's disease. Mov Disord. 5:66-70
Golbe, L.I., G. Di Iorio, V. Bonavita, et al. 1990 A
large kindred with autosomal dominant Parkinson's
disease. Ann Neurol. 27:276-282
Groves, P.M. 1983 A theory of the functional
organization of the neostriatum and the neostriatal
control of voluntary movement. Brain Res. Rev.=20
5:109-132
Hirsch, E.C., A.M. Graybiel, Y. Agid. 1989 Selective
vulnerability of pigmented dopaminergic neurons in
Parkinson's disease. Acta Neurol Scand. 126:19-22
Hoehn, M.M. and M.D. Yahr. 1967 Parkinsonism: onset,
progression, and mortality. Neurology 17:427-442
Jankovic, J. and A. Reches. 1986 Parkinson's disease in
monozygotic twins. Ann Neurol. 19:405-408
Jankovic, J., M. McDermott, J. Carter, et al. 1990=20
Variable expression of Parkinson's disease: a base-line
analysis of the DATATOP cohort. Neurology 40:1529-1534
Kanazawa, I., M. Murata, and M, Kimura. 1993. Roles of
dopamine and its receptors in generation of choreic
movements. Pages 107-112 in H. Narabayashi, T. Nagatsu,
N. Yanagisawa, and Y. Mizuno, eds. Advances in neurology
(vol. 60): Parkinson's disease-from basic research to
treatment. New York, NY
Kimura, M., T. Aosaki, and A. Ishida. 1993. =20
Neurophysiological aspects of the differential roles of
the putamen and caudate nucleus in voluntary movement.=20
Pages 62-70 in H. Narabayashi, T. Nagatsu, N.
Yanagisawa, and Y. Mizuno, eds. Advances in neurology
(vol. 60): Parkinson's disease-from basic research to
treatment. New York, NY
Kitai, S.T. and D.J. Surmeier. 1993. Cholinergic and
dopaminergic modulation of potassium conductances in=20
neostriatal neurons. Pages 40-52 in H. Narabayashi, T.
Nagatsu, N. Yanagisawa, and Y. Mizuno, eds. Advances in
neurology (vol. 60): Parkinson's disease-from basic
research to treatment. New York, NY
Koller, W.C., B. Vetere-Overfield, et al. 1990=20
Environmental risk factors in Parkinson's disease.=20
Neurology 40:1218-1221
Kopin, I.J., and S.P. Markey. 1988 MPTP toxicity:
implications for research in Parkinson's disease. Ann.
Rev. Neurosci. 11:81-96.
Krusz, J.C., W.C. Koller, D.K. Ziegler. 1987 Historical
review: abnormal movements associated with epidemic
encephalitis lethargica. Mov Disord. 2:137-141
Kurtzke, J.F. and F.M. Murphy. 1990 The changing
patterns of death rates in parkinsonism. Neurology
40:42-49
Lance, J.W. 1980 The control of muscle tone, reflexes,
and movement: Robert Wartenberg lecture. Neurology
30:1303-1313
Madrazo, I., R. Drucker-Col=A1n, V. D=A1az, J. Mart=A1nez-Mata,
C. Torres., J.J. Becerril. 1987 Open microsurgical
autografts of adrenal medulla to the right caudate
nucleus in two patients with intractable Parkinson's
disease. New Eng. J. Med 316:831-834
Matthews, R.T. and D.C. German. 1986 Evidence for a
functional role of dopamine type-I (D-1) receptors in the
substantia nigra of rats. Eur. J. Pharmacol. 120:87-93
McGeer, P.L. and E.G. McGeer. 1993. Neurotransmitters
and their receptors in the basal ganglia. Pages 93-101
in H. Narabayashi, T. Nagatsu, N. Yanagisawa, and Y.
Mizuno, eds. Advances in neurology (vol. 60):
Parkinson's disease-from basic research to treatment.=20
New York, NY
Nagatsu, T. 1993. Biochemical aspects of Parkinson's
disease. Pages 165-174 in H. Narabayashi, T. Nagatsu,
N. Yanagisawa, and Y. Mizuno, eds. Advances in neurology
(vol. 60): Parkinson's disease-from basic research to
treatment. New York, NY
Naoi, M., P. Dostert, M. Yoshida, and T. Nagatsu. 1993.=20
N-methylated tetrahydroisoquinolines as dopaminergic
neurotoxins. Pages 212-217 in H. Narabayashi, T.
Nagatsu, N. Yanagisawa, and Y. Mizuno, eds. Advances in
neurology (vol. 60): Parkinson's disease-from basic
research to treatment. New York, NY
Nomoto, M. and T. Fukuda. 1993. The effects of D1 and
D2 dopamine receptor agonist and antagonist on
parkinsonism in chronic MPTP-treated monkeys. Pages
119-122 in H. Narabayashi, T. Nagatsu, N. Yanagisawa,
and Y. Mizuno, eds. Advances in neurology (vol. 60):
Parkinson's disease-from basic research to treatment.=20
New York, NY
Olanow, C.W. 1990 Oxidation reactions in Parkinson's
disease. Neurology 40:32-37
Olanow, C.W. 1993 A radical hypothesis for
neurodegeneration. Trends Neurosci. 16:439-445.
Parent, A. and B. Lavoie. 1993. The heterogeneity of
the mesostriatal dopaminergic system as revealed in
normal and parkinsonian monkeys. Pages 25-33 in H.
Narabayashi, T. Nagatsu, N. Yanagisawa, and Y. Mizuno,
eds. Advances in neurology (vol. 60): Parkinson's
disease-from basic research to treatment. New York, NY
Parkinson Study Group. 1993 Effects of tocopherol and
deprenyl on the progression of disability in early
Parkinson's disease. New Eng. J. Med 328:176-183
Poewe, W., E. Daramat, G.W. Kemmler, and F. Gerstenbrand.
1990. The premorbid personality of patients with
Parkinson's disease: a comparative study with healthy
controls and patients with essential tremor. Pages
339-342 in T. Nagatsu, et al, eds. Advances in
neurology (vol. 53): Parkinson's disease: anatomy,
pathology, and therapy. New York, NY
Rascol, O.J., U. Sabatini, F. Chollet, J.L. Montastruc,
J.P. Marc-Vergnes, and A. Rascol. 1993. Impaired
activity of the supplementary motor area in akinetic
patients with Parkinson's disease. Pages 419-421 in H.
Narabayashi, T. Nagatsu, N. Yanagisawa, and Y. Mizuno,
eds. Advances in neurology (vol. 60): Parkinson's
disease-from basic research to treatment. New York, NY=20
Rogawski, M.A. 1993 Therapeutic potential of excitatory
amino acid antagonists: channel blockers and 2,3-
benzodiazepines. Trends Pharmacol. Sci. 14(9):325-333.
Roy, M., L. Boyer, A. Barbeau. 1983 A prospective study
of 50 cases of familial Parkinson's disease. Can J
Neural Sci. 10:37-42
Stacy, M. and J. Jankovic. 1992. Clinical and
neurobiological aspects of Parkinson's disease. Pages
10-31 in S.J. Huber and J.L. Cummings, eds. Parkinson's
disease: neurobehavioral aspects. New York, NY
Walters, J.W., et al. 1987 D1 dopamine receptor
activation required for postsynaptic expression of D2
agonist affects. Science 236:719-722
=20
Wichmann, T. and M.R. DeLong. 1993. Pathophysiology of
parkinsonian motor abnormalities. Pages 53-61 in H.
Narabayashi, T. Nagatsu, N. Yanagisawa, and Y. Mizuno,
eds. Advances in neurology (vol. 60): Parkinson's
disease-from basic research to treatment. New York, NY
Yoshida, M. 1993. The neuronal mechanism underlying
parkinsonism and dyskinesia, and differential roles of
the putamen and caudate nucleus. Pages 71-77 in H.
Narabayashi, T. Nagatsu, N. Yanagisawa, and Y. Mizuno,
eds. Advances in neurology (vol. 60): Parkinson's
disease-from basic research to treatment. New York, NY
Yurek, D.M. and J.R. Sladek, Jr. 1990 Dopamine cell
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D
Barbara [log in to unmask]
HSC 2J22=09=09=09=09=09905-525-9140, ext. 22403
=09=09=09School of Nursing
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D
